Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors

Hartmut Porst, Gerald B. Brock, Krzysztof Kula, Ignacio Moncada, Francesco Montorsi, Bruce R. Basson, Kraig Kinchen, Antonio Aversa

Research output: Contribution to journalArticlepeer-review

Abstract

Previous studies established the efficacy of oncedaily tadalafil for men with erectile dysfunction. However, no trial has focused on the effects of such treatment on men without previous experience using oral phosphodiesterase type 5 inhibitors. Patients were randomized (2:1) to once-daily tadalafil 5mg (with possible down-titration to 2.5mg; n=146) or placebo (n=69) for 12 weeks. Among 215 patients (mean age, 52 years), once-daily tadalafil treatment resulted in 61.7% of study participants reporting their ability to achieve and maintain erections as being much better or very much better (vs 21.7% on placebo; P

Original languageEnglish
Pages (from-to)1305-1322
Number of pages18
JournalJournal of Andrology
Volume33
Issue number6
DOIs
Publication statusPublished - 2012

Keywords

  • Drug therapy
  • Efficacy
  • Endothelium
  • Erection
  • Morning
  • Nocturnal
  • Peripheral arterial tonometry
  • Phosphodiesterases
  • Psychosocial assessments
  • Tolerability
  • Treatment outcome

ASJC Scopus subject areas

  • Urology
  • Reproductive Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors'. Together they form a unique fingerprint.

Cite this